Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Use Of Rearranged Immune Receptor Sequencing To Measure Minimal Residual Disease (MRD) In Bone Marrow, Cerebrospinal Fluid and Testes In Relapsed Childhood Acute Lymphoblastic Leukemia

Norman J. Lacayo, MD, Li Weng, PhD, Charles Gawad, MD, Malek Faham, MD, PhD, Gary V Dahl, MD

Blood (2013) 122 (21): 4984.

https://doi.org/10.1182/blood.V122.21.4984.4984

Published: 2013

Journal Articles

Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy

Seth E Karol, MD, Elaine Coustan-Smith, MS, Xueyuan Cao, PhD, Sheila A Shurtleff, PhD, Susana C Raimondi, PhD, John K Choi, MD, PhD, Raul C Ribeiro, MD, Gary V Dahl, MD, W Paul Bowman, MD, Jeffrey W Taub, MD, Barbara Degar, MD, Wing Leung, MD, PhD, James R Downing, MD, Ching-Hon Pui, MD, Jeffrey E Rubnitz, MD, PhD, Dario Campana, MD, PhD, Hiroto Inaba, MD, PhD

Blood (2013) 122 (21): 490.

https://doi.org/10.1182/blood.V122.21.490.490

Published: 2013

Journal Articles

Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort

Charles Gawad, MD, Michael J. Borowitz, MD, PhD, Gary V. Dahl, MD, Meenakshi Devidas, PhD, Malek Faham, MD, PhD, Martin Moorhead, PhD, Brent L. Wood, MD, PhD, Jianbiao Zheng, PhD, Mignon L. Loh, MD, Norman J. Lacayo, MD

Blood (2012) 120 (21): 1440.

https://doi.org/10.1182/blood.V120.21.1440.1440

Published: 2012

Journal Articles

L-Asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a Large Compassionate Use Protocol.

Paul V. Plourde, MD, Sima Jeha, MD, Nobuko Hijiya, MD, Frank G Keller, MD, Susan R. Rheingold, MD, Zoann E. Dreyer, MD, Gary V. Dahl, MD, Taheri Mercedes, MD, Tim Corn, MD

Blood (2012) 120 (21): 2568.

https://doi.org/10.1182/blood.V120.21.2568.2568

Published: 2012

Journal Articles

Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,

Norman J. Lacayo, MD, Todd A. Alonzo, PhD, Urte Gayko, Ph.D., Matt Westfall, Ph.D., Norman Purvis, Ph.D., Santosh Putta, Ph.D., James Hackett, Ph.D., Aileen Cleary Cohen, MD, PhD, Robert B. Gerbing, M.A., Gary V Dahl, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, Ph.D.

Blood (2011) 118 (21): 3544.

https://doi.org/10.1182/blood.V118.21.3544.3544

Published: 2011

Journal Articles

Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region in Diagnostic Samples of Pediatric Acute Lymphoblastic Leukemia Identifies Hundreds of Clonal Subpopulations with Multiple Immunophenotypes

Charles Gawad, MD, Malek Faham, MD, PhD, Tom Willis, PhD, Martin Moorhead, PhD, Victoria Carlton, PhD, Jianbiao Zheng, PhD, Mark Klinger, Gary V Dahl, MD, Norman J. Lacayo, MD

Blood (2011) 118 (21): 1436.

https://doi.org/10.1182/blood.V118.21.1436.1436

Published: 2011

Journal Articles

2008 WHO Classification of Pediatric AML.

Kara L. Davis, DO, Amy Heerema-McKenney, MD, Lisa Ma, Daniel A. Arber, MD, Gary V Dahl, MD

Blood (2010) 116 (21): 1044.

https://doi.org/10.1182/blood.V116.21.1044.1044

Published: 2010

Journal Articles

Molecular Inversion Probes (MIPs) Identify Novel Areas of Allelic Imbalance in Childhood Leukemia.

Joshua D. Schiffman, MD, Katrina Welch, Ronald Davis, PhD, Norman J. Lacayo, MD, Gary V. Dahl, MD, Yuker Wang, PhD, Malek Faham, MD, James M. Ford, MD, Hanlee P. Ji, MD

Blood (2007) 110 (11): 1438.

https://doi.org/10.1182/blood.V110.11.1438.1438

Published: 2007

Journal Articles

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

Dennis J. Kuo, MD, Norman J. Lacayo, MD, Steven Buck, MS, Ron Yu, MA, Chitra Saraiya, MS, Lorrie Douglas, BS, Howard Weinstein, MD, Myron Chang, MD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Gary V. Dahl, MD, Branimir Sikic, MD, Yaddanapudi Ravindranath, MD

Blood (2004) 104 (11): 1130.

https://doi.org/10.1182/blood.V104.11.1130.1130

Published: 2004

Journal Articles

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Norman J. Lacayo, MD, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Dennis J. Kuo, MD, Ron Yu, MA, Myron N. Chang, PhD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir I. Sikic, MD, Howard Weinstein, MD, Gary V. Dahl, MD

Blood (2004) 104 (11): 570.

https://doi.org/10.1182/blood.V104.11.570.570

Published: 2004

NARROW

Use Of Rearranged Immune Receptor Sequencing To Measure Minimal Residual Disease (MRD) In Bone Marrow, Cerebrospinal Fluid and Testes In Relapsed Childhood Acute Lymphoblastic Leukemia

Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy

Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort

L-Asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a Large Compassionate Use Protocol.

Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,

Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region in Diagnostic Samples of Pediatric Acute Lymphoblastic Leukemia Identifies Hundreds of Clonal Subpopulations with Multiple Immunophenotypes

2008 WHO Classification of Pediatric AML.

Molecular Inversion Probes (MIPs) Identify Novel Areas of Allelic Imbalance in Childhood Leukemia.

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only